Sutro Biopharma
Clinical-stage biotechnology company focused on design, discovery, and development of next-generation antibody-drug conjugates (single- and dual-payload) and related protein therapeutics using a cell-free protein synthesis and site-specific conjugation approach. The company advances preclinical and early clinical programs, operates cGMP manufacturing capabilities (historically) and collaborates with pharma partners for discovery, development and manufacturing.
Industries
Nr. of Employees
large (251-1000)
Sutro Biopharma
Patents
Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
US-12540197-B2
View Details5H-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof
US-12534465-B2
View DetailsAnti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates
US-12427201-B2
View DetailsAntibodies with engineered CH2 domains, compositions thereof and methods of using the same
US-12398197-B2
View Details
Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
US-12540197-B2
View Details5H-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof
US-12534465-B2
View DetailsAnti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates
US-12427201-B2
View DetailsAntibodies with engineered CH2 domains, compositions thereof and methods of using the same
US-12398197-B2
View DetailsProducts
STRO-004 (Tissue Factor-directed exatecan ADC)
Next-generation exatecan-based ADC targeting Tissue Factor with site-specific conjugation and high drug-to-antibody ratio; advancing in Phase 1 solid tumor studies.
STRO-006 (Integrin β6-directed ADC)
Integrin β6-targeting ADC designed to deliver exatecan payloads with optimized exposure and reduced platform toxicity; progressing toward clinical development.
STRO-227 (Dual-payload PTK7-directed ADC)
Dual-payload ADC combining complementary cytotoxic payloads to target PTK7-positive tumors; preclinical data indicate improved activity vs single-payload ADCs.
Luveltamab tazevibulin (FRα-targeting ADC, previously STRO-002)
Folate receptor-α targeting ADC evaluated in dose-optimization and Phase 1 studies for platinum-resistant ovarian cancer; demonstrated clinical activity in certain cohorts but later deprioritized for internal development.
STRO-004 (Tissue Factor-directed exatecan ADC)
Next-generation exatecan-based ADC targeting Tissue Factor with site-specific conjugation and high drug-to-antibody ratio; advancing in Phase 1 solid tumor studies.
STRO-006 (Integrin β6-directed ADC)
Integrin β6-targeting ADC designed to deliver exatecan payloads with optimized exposure and reduced platform toxicity; progressing toward clinical development.
STRO-227 (Dual-payload PTK7-directed ADC)
Dual-payload ADC combining complementary cytotoxic payloads to target PTK7-positive tumors; preclinical data indicate improved activity vs single-payload ADCs.
Luveltamab tazevibulin (FRα-targeting ADC, previously STRO-002)
Folate receptor-α targeting ADC evaluated in dose-optimization and Phase 1 studies for platinum-resistant ovarian cancer; demonstrated clinical activity in certain cohorts but later deprioritized for internal development.
Services
Research and development collaborations to design and produce engineered protein therapeutics including ADCs and bispecific antibodies using cell-free expression and site-specific conjugation.
Production of clinical supplies using scaled cell-free processes under cGMP for early clinical programs.
Research and development collaborations to design and produce engineered protein therapeutics including ADCs and bispecific antibodies using cell-free expression and site-specific conjugation.
Production of clinical supplies using scaled cell-free processes under cGMP for early clinical programs.
Expertise Areas
- Antibody-drug conjugate (ADC) discovery and development
- Cell-free protein synthesis and protein engineering
- Site-specific conjugation and non-natural amino acid incorporation
- Preclinical pharmacology and in vivo tumor models (xenograft, PDX)
Key Technologies
- Cell-free protein synthesis
- Site-specific conjugation chemistry
- Non-natural amino acid incorporation
- Single- and dual-payload ADC engineering
News & Updates
Company announced prioritization of exatecan and dual-payload ADC programs, plans to file three INDs over three years, transition in CEO, and plan to externalize manufacturing operations.
Late-breaking oral presentation reporting dose-optimization results for a folate receptor–targeting ADC in platinum-resistant ovarian cancer, including response rates and safety observations.
Peer-reviewed study showed production of a disulfide-bonded cytokine using an E. coli-based open cell-free system with linear scalability and production titers suitable for clinical development.
Multiple presentations and posters at scientific conferences (World ADC Summit, AACR, ASCO, PEGS, SITC) describing ADC design, clinical data and preclinical results.
Collaborations and agreements with pharmaceutical organizations for discovery, development and manufacturing (examples include Pfizer, Celgene/Celgene Corporation collaborations, and collaborations for vaccine production).
Established a cGMP manufacturing facility to produce clinical supplies using the cell-free production platform; demonstrated ability to produce clinical-grade materials and later transitioned manufacturing strategy to external partners.
Company announced prioritization of exatecan and dual-payload ADC programs, plans to file three INDs over three years, transition in CEO, and plan to externalize manufacturing operations.
Late-breaking oral presentation reporting dose-optimization results for a folate receptor–targeting ADC in platinum-resistant ovarian cancer, including response rates and safety observations.
Peer-reviewed study showed production of a disulfide-bonded cytokine using an E. coli-based open cell-free system with linear scalability and production titers suitable for clinical development.
Multiple presentations and posters at scientific conferences (World ADC Summit, AACR, ASCO, PEGS, SITC) describing ADC design, clinical data and preclinical results.
Collaborations and agreements with pharmaceutical organizations for discovery, development and manufacturing (examples include Pfizer, Celgene/Celgene Corporation collaborations, and collaborations for vaccine production).
Established a cGMP manufacturing facility to produce clinical supplies using the cell-free production platform; demonstrated ability to produce clinical-grade materials and later transitioned manufacturing strategy to external partners.